(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hamas hands over another body in the Gaza Strip - 2Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- 3Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- 4Jennifer Lawrence and Josh Hutcherson to reprise their roles for new 'Hunger Games' movie 'Sunrise on the Reaping'
- 5Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Five held on suspicion of planning attack on German Christmas market
- Reports: Germany plans expansion of foreign intelligence powers
- Find Serenity: 10 Stunning Setting up camp Areas
- The Best 15 Applications for Efficiency and Association
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Island Travel Guide: Must-Visit Objections for 2024
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 21 Things You Ought to Never Share with Your Childless Companion
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
